🏆Prof. Ruipeng Jia, 🎉 Congratulations on Your Best Researcher Award! 🏆

• Prof. Ruipeng Jia, Nanjing First Hospital, China- Leading Researcher in Tissue Engineering

Dr. Ruipeng Jia, 🎉 Heartiest Congratulations on being honored with the Best Researcher Award! 🏆 Your unwavering commitment to groundbreaking research in urology and tissue engineering has set a remarkable standard in our field. 🌟 Your dedication and contributions are truly inspiring, and this recognition is well-deserved.

May this achievement be a testament to your passion for advancing medical knowledge and improving patient outcomes. 🚀 Wishing you continued success on your journey of exploration and discovery. Keep shining and making a positive impact on the world of research! 👏👨‍🔬

Professional Profiles:

• Scopus Profile

Education Background

• M.D., Shandong University, P.R. China – July 1999
  • Major: Urology

Working Experiences

• Director of Urology, Nanjing First Hospital – June 2011 to September 2013
• Head of Urology, Nanjing First Hospital – September 2013 to Present

Projects

1. Technology development and clinical transformation of real-time navigation imaging system in minimally invasive surgery for benign prostatic hyperplasia
   • Jiangsu Provincial Key Research and Development Program – 2024.1 to 2026.12
2. Mechanism of action of flexible graphene microarray gels compounded with Ad-SVF to promote bladder aging-mediated repair of UAB forced urinary muscle (92049111)
   • Natural Science Foundation of China – 2020.01 to 2022.12
3. Mechanism of action of ad-SVF/ECM gel complex in repairing renal ischemia-reperfusion injury (BE2017615)
   • Natural Science Foundation of China – 2018.08 to 2020.12

Social Services

Ruipeng Jia is actively involved in various medical associations, holding leadership positions and contributing to committees in urology, male science, prostate health management, rehabilitation, sexology, immunology, and more.

This profile showcases a well-rounded professional with a strong academic background, significant research contributions, and active engagement in the medical community.

Research Focus

Ruipeng Jia’s primary research focus lies in urology, with a particular emphasis on the following areas:

• Bladder Tissue Engineering: Developing artificial scaffolds and utilizing adipose-derived mesenchymal stem cells for bladder tissue engineering.
• Renal Cell Carcinoma: Molecular typing and prognosis assessment using MicrorNa-based approaches.
• Prostate Cancer: Investigating the role of Prostate-specific membrane antigen in cancer progression and the synthesis of arginine and proline.
• Stromal Vascular Fraction (SVF): Utilizing SVF in therapeutic applications for conditions like underactive bladder and testicular injury.
• Extracellular Vesicles: Studying the therapeutic potential of extracellular vesicles derived from various sources.

Professional Journey

Ruipeng Jia has held key positions at Nanjing First Hospital, including Director and Head of the Urology Department. His career trajectory has seen a progression from clinical roles to leadership positions. Additionally, he has actively participated in multiple research projects, contributing significantly to the field of urology.

Honors & Awards

• Jiangsu Province New Technology Introduction Award (2019):
  • For work on MicrorNa-based Molecular Typing and Prognosis Assessment of Renal Cell Carcinoma.
• Jiangsu Province New Technology Introduction Award (2013):
  • Recognized for the Application of inducible Prostaglandin synthetase mPGES1/COX2 in Hormone Independent Prediction and Treatment of prostate cancer.
• Jiangsu Province New Technology Introduction Award (2016):
  • Acknowledged for MicrorNa-based Molecular Typing and Prognosis Assessment of Renal Cell Carcinoma.

Publications & Contributions

Ruipeng Jia has made significant contributions to the scientific community through a series of impactful publications. Some notable contributions include:

• Publications (Selected)

  1. Negatively charged bladder acellular matrix loaded with positively charged adipose-derived mesenchymal stem cell-derived small extracellular vesicles for bladder tissue engineering. – J Control Release. 2023 Nov 7.
  2. Construction of tissue-engineered bladders using an artificial acellular nanocomposite scaffold loaded with stromal vascular fraction secretome. – Acta Biomater. 2023 Sep 1.
  3. Exosomal AP000439.2 from clear cell renal cell carcinoma induces M2 macrophage polarization to promote tumor progression through activation of STAT3. – Cell Commun Signal. 2022 Sep 24.
  4. Sig1R activates extracellular matrix-induced bladder cancer cell proliferation and angiogenesis by combining β-integrin. – Aging (Albany NY). 2023 May 16.
  5. Therapeutic effect of adipose stromal vascular fraction spheroids for partial bladder outlet obstruction induced underactive bladder. – Stem Cell Res Ther. 2022 Feb 9.

Research Timeline

1. 2024 – 2026:
   • Leading a project on the development and clinical transformation of a real-time navigation imaging system for minimally invasive surgery in benign prostatic hyperplasia.
2. 2020 – 2022:
   • Investigating the mechanism of action of flexible graphene microarray gels for bladder aging-mediated repair.
   • Studying the mechanism of action of ad-SVF/ECM gel complex in repairing renal ischemia-reperfusion injury.
3. 2019:
   • Awarded for the protective effects of uncultured adipose-derived stromal vascular fraction on testicular injury induced by torsion-detorsion in rats.
4. 2018 – 2020:
   • Researching the mechanism of action of ad-SVF/ECM gel complex in repairing renal ischemia-reperfusion injury.
5. 2016:
   • Recognized for MicrorNa-based Molecular Typing and Prognosis Assessment of Renal Cell Carcinoma.
6. 2013:
   • Awarded for the application of inducible Prostaglandin synthetase mPGES1/COX2 in hormone-independent prediction and treatment of prostate cancer.
7. 2011 – 2013:
   • Served as Director and subsequently Head of Urology at Nanjing First Hospital.

Ruipeng Jia’s research journey is characterized by a diverse range of projects, active involvement in clinical and leadership roles, and a consistent dedication to advancing knowledge in urology.